{
  "trial_id": "NCT00988208",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, ECOG performance status, life expectancy, serum testosterone levels, metastatic adenocarcinoma confirmation, disease progression status, prior therapy history, prior chemotherapy history, prior radiation therapy history, prior surgery history, concurrent anti-androgen therapy status, serum chemistry values, hematology laboratory values, cardiac disease history, thrombotic events history, peripheral neuropathy history, hypersensitivity reaction history, paraplegia status, CNS or brain metastases history, history of other malignancies, concurrent use of alternative cancer therapies.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "ECOG Performance Status",
          "ECOG performance status"
        ],
        [
          "Type of Disease Progression",
          "disease progression status"
        ],
        [
          "Prior Radiotherapy",
          "prior radiation therapy history"
        ],
        [
          "Prior Cancer Surgery",
          "prior surgery history"
        ],
        [
          "Other Prior Anti-Cancer Therapy",
          "prior therapy history"
        ],
        [
          "Baseline PSA (Prostate Specific Antigen) Levels",
          "serum testosterone levels"
        ]
      ],
      "remaining_reference_features": [
        "Sex/Gender",
        "Region of Enrollment",
        "Race",
        "Weight",
        "Height",
        "Body Mass Index",
        "Categorical",
        "Metastatic Sites of Disease Outside of Prostate"
      ],
      "remaining_candidate_features": [
        "life expectancy",
        "metastatic adenocarcinoma confirmation",
        "prior chemotherapy history",
        "concurrent anti-androgen therapy status",
        "serum chemistry values",
        "hematology laboratory values",
        "cardiac disease history",
        "thrombotic events history",
        "peripheral neuropathy history",
        "hypersensitivity reaction history",
        "paraplegia status",
        "CNS or brain metastases history",
        "history of other malignancies",
        "concurrent use of alternative cancer therapies"
      ]
    },
    "processed-gen-response": "Age, ECOG performance status, life expectancy, serum testosterone levels, metastatic adenocarcinoma confirmation, disease progression status, prior therapy history, prior chemotherapy history, prior radiation therapy history, prior surgery history, concurrent anti-androgen therapy status, serum chemistry values, hematology laboratory values, cardiac disease history, thrombotic events history, peripheral neuropathy history, hypersensitivity reaction history, paraplegia status, CNS or brain metastases history, history of other malignancies, concurrent use of alternative cancer therapies."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG performance status, Serum testosterone levels, Metastatic disease status, Serum Prostate Specific Antigen (PSA) level, Prior hormonal therapy, Prior radiation therapy, Prior surgery, Baseline laboratory values (serum chemistry, hematology), History of cardiac disease, History of thrombotic events, History of peripheral neuropathy, History of hypersensitivity reactions, History of CNS or brain metastases, History of other malignancies,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex/Gender",
          "Sex: Male"
        ],
        [
          "Race",
          "Race/Ethnicity"
        ],
        [
          "ECOG Performance Status",
          "ECOG performance status"
        ],
        [
          "Type of Disease Progression",
          "Metastatic disease status"
        ],
        [
          "Prior Radiotherapy",
          "Prior radiation therapy"
        ],
        [
          "Prior Cancer Surgery",
          "Prior surgery"
        ],
        [
          "Baseline PSA (Prostate Specific Antigen) Levels",
          "Serum Prostate Specific Antigen (PSA) level"
        ]
      ],
      "remaining_reference_features": [
        "Region of Enrollment",
        "Weight",
        "Height",
        "Body Mass Index",
        "Categorical",
        "Other Prior Anti-Cancer Therapy",
        "Metastatic Sites of Disease Outside of Prostate"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "Serum testosterone levels",
        "Prior hormonal therapy",
        "Baseline laboratory values (serum chemistry, hematology)",
        "History of cardiac disease",
        "History of thrombotic events",
        "History of peripheral neuropathy",
        "History of hypersensitivity reactions",
        "History of CNS or brain metastases",
        "History of other malignancies"
      ]
    },
    "processed-gen-response": "Age, Sex: Male, Race/Ethnicity, Region of Enrollment, ECOG performance status, Serum testosterone levels, Metastatic disease status, Serum Prostate Specific Antigen (PSA) level, Prior hormonal therapy, Prior radiation therapy, Prior surgery, Baseline laboratory values (serum chemistry, hematology), History of cardiac disease, History of thrombotic events, History of peripheral neuropathy, History of hypersensitivity reactions, History of CNS or brain metastases, History of other malignancies"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Male, ECOG Performance Status, Life Expectancy, Serum Testosterone Levels, Serum Prostate Specific Antigen (PSA) Level, Radiological Progression, Number of Bone Lesions, Prior Hormonal Therapy, Prior Radiation Therapy, Prior Surgery, Concurrent Anti-androgen Therapy, Abnormal Serum Chemistry or Hematology Laboratory Values, Active Cardiac Disease, Thrombotic or Thromboembolic Events, Peripheral Neuropathy, Hypersensitivity Reaction to Drugs Formulated with Polysorbate 80, Paraplegia, Central Nervous System (CNS) or Brain Metastases, History of Malignancies Other than Prostate Cancer.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex/Gender",
          "Sex: Male"
        ],
        [
          "ECOG Performance Status",
          "ECOG Performance Status"
        ],
        [
          "Type of Disease Progression",
          "Radiological Progression"
        ],
        [
          "Prior Radiotherapy",
          "Prior Radiation Therapy"
        ],
        [
          "Prior Cancer Surgery",
          "Prior Surgery"
        ],
        [
          "Other Prior Anti-Cancer Therapy",
          "Prior Hormonal Therapy"
        ],
        [
          "Baseline PSA (Prostate Specific Antigen) Levels",
          "Serum Prostate Specific Antigen (PSA) Level"
        ]
      ],
      "remaining_reference_features": [
        "Region of Enrollment",
        "Race",
        "Weight",
        "Height",
        "Body Mass Index",
        "Categorical",
        "Metastatic Sites of Disease Outside of Prostate"
      ],
      "remaining_candidate_features": [
        "Life Expectancy",
        "Serum Testosterone Levels",
        "Number of Bone Lesions",
        "Concurrent Anti-androgen Therapy",
        "Abnormal Serum Chemistry or Hematology Laboratory Values",
        "Active Cardiac Disease",
        "Thrombotic or Thromboembolic Events",
        "Peripheral Neuropathy",
        "Hypersensitivity Reaction to Drugs Formulated with Polysorbate 80",
        "Paraplegia",
        "Central Nervous System (CNS) or Brain Metastases",
        "History of Malignancies Other than Prostate Cancer"
      ]
    },
    "processed-gen-response": "Age, Sex: Male, ECOG Performance Status, Life Expectancy, Serum Testosterone Levels, Serum Prostate Specific Antigen (PSA) Level, Radiological Progression, Number of Bone Lesions, Prior Hormonal Therapy, Prior Radiation Therapy, Prior Surgery, Concurrent Anti-androgen Therapy, Abnormal Serum Chemistry or Hematology Laboratory Values, Active Cardiac Disease, Thrombotic or Thromboembolic Events, Peripheral Neuropathy, Hypersensitivity Reaction to Drugs Formulated with Polysorbate 80, Paraplegia, Central Nervous System (CNS) or Brain Metastases, History of Malignancies Other than Prostate Cancer."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, ECOG performance status, life expectancy, serum testosterone levels, serum PSA levels, number of bone lesions, prior hormonal therapy, prior radiation therapy, prior surgery, presence of cardiac disease, presence of peripheral neuropathy, presence of CNS or brain metastases, history of malignancies other than prostate cancer.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "ECOG Performance Status",
          "ECOG performance status"
        ],
        [
          "Baseline PSA (Prostate Specific Antigen) Levels",
          "serum PSA levels"
        ],
        [
          "Prior Radiotherapy",
          "prior radiation therapy"
        ],
        [
          "Prior Cancer Surgery",
          "prior surgery"
        ],
        [
          "Other Prior Anti-Cancer Therapy",
          "prior hormonal therapy"
        ]
      ],
      "remaining_reference_features": [
        "Sex/Gender",
        "Region of Enrollment",
        "Race",
        "Weight",
        "Height",
        "Body Mass Index",
        "Categorical",
        "Type of Disease Progression",
        "Metastatic Sites of Disease Outside of Prostate"
      ],
      "remaining_candidate_features": [
        "life expectancy",
        "serum testosterone levels",
        "number of bone lesions",
        "presence of cardiac disease",
        "presence of peripheral neuropathy",
        "presence of CNS or brain metastases",
        "history of malignancies other than prostate cancer."
      ]
    },
    "processed-gen-response": "Age, ECOG performance status, life expectancy, serum testosterone levels, serum PSA levels, number of bone lesions, prior hormonal therapy, prior radiation therapy, prior surgery, presence of cardiac disease, presence of peripheral neuropathy, presence of CNS or brain metastases, history of malignancies other than prostate cancer."
  }
}